Liquid Biopsy Market worth 1.66 Billion USD by 2021

1
MarketsandMarkets Presents
Liquid Biopsy Market worth 1.66 Billion USD by
2021
http//www.marketsandmarkets.com/Market-Reports/li
quid-biopsy-market-13966350.html
2
The report "Liquid Biopsy Market Cancer Type
(Lung, Breast, Colorectal, Prostate, Liver),
Circulating Biomarkers (Circulating Tumor Cells,
Circulating Tumor DNA), Product (Instruments,
Software), End User (Reference Laboratory,
Research Centers) - Forecast to 2021", provides a
detailed overview of the major drivers,
restraints, challenges, opportunities, current
market trends, and strategies impacting the
liquid biopsy market along with the estimates and
forecasts of the revenue. Browse 75 market data
Tables and 74 Figures spread through 160 Pages
and in-depth TOC on "Liquid Biopsy Market Cancer
Type (Lung, Breast, Colorectal, Prostate, Liver),
Circulating Biomarkers (Circulating Tumor Cells,
Circulating Tumor DNA), Product (Instruments,
Software), End User (Reference Laboratory,
Research Centers) - Forecast to
2021" http//www.marketsandmarkets.com/Market-Rep
orts/liquid-biopsy-market-13966350.html  
http//www.marketsandmarkets.com/Market-Reports/li
quid-biopsy-market-13966350.html
3
Early buyers will receive 10 customization on
this report.

 
http//www.marketsandmarkets.com/Market-Reports/li
quid-biopsy-market-13966350.html
4

• The liquid biopsy market is expected to reach USD
  1.66 Billion by 2021 from USD 0.58 Billion in
  2016, growing at a CAGR of 23.4 during this
  period.
• A number of factors, such as the rising incidence
  of cancer, benefits of liquid biopsy over solid
  tumor biopsy, technological advancements,
  availability of funding, and growing awareness
  about liquid biopsy through conferences and
  government initiatives, are driving the growth of
  the market. However, unclear regulatory and
  reimbursement scenario is the major area of
  concern in this market.

http//www.marketsandmarkets.com/Market-Reports/li
quid-biopsy-market-13966350.html
5

• In this report, the liquid biopsy market is
  segmented on the basis of cancer type,
  circulating biomarkers, products services, end
  users, and regions. Based on cancer type, the
  market is segmented into lung cancer, breast
  cancer, colorectal cancer, prostate cancer, liver
  cancer, and other cancers. The other cancers
  segment includes melanoma, bladder cancer, and
  ovarian cancer. In 2016, the lung cancer segment
  is expected to account for the largest share of
  the market, followed by breast cancer.

http//www.marketsandmarkets.com/Market-Reports/li
quid-biopsy-market-13966350.html
6

• Based on circulating biomarkers, the liquid
  biopsy market is categorized into four major
  segments, namely, circulating tumor cells (CTCs),
  circulating tumor DNA (ctDNA), Extracellular
  Vesicles (EVs), and other biomarkers. The other
  biomarkers segment includes circulating RNA and
  proteins. The circulating tumor cells segment is
  expected to account for the largest share of the
  global market in 2016, followed by the
  circulating tumor DNA segment. Based on products
  and services, the market is segmented into
  instruments, reagents, and services and software.

http//www.marketsandmarkets.com/Market-Reports/li
quid-biopsy-market-13966350.html
7

• Based on end user, the liquid biopsy market is
  segmented into reference laboratories,
  hospital/physician laboratories, academic and
  research centers, and other end users. The other
  end-users segment includes public health
  laboratories, pathology laboratories, and small
  molecular laboratories.

http//www.marketsandmarkets.com/Market-Reports/li
quid-biopsy-market-13966350.html
8

• In 2016, North America is expected to account for
  the largest share of the global market. The large
  share of this regional segment can be attributed
  to factors such as easy accessibility and high
  adoption of advanced diagnostic technologies,
  such as PCR and NGS, among healthcare
  professionals increasing prevalence of cancer in
  the U.S. and Canada and continuous technological
  advancements in liquid biopsy. The Asia-Pacific
  market, however, is estimated to witness the
  highest growth during the forecast period owing
  to the increasing focus of market players on this
  region.

http//www.marketsandmarkets.com/Market-Reports/li
quid-biopsy-market-13966350.html
9

• Biocept Inc. (U.S.), Myriad Genetics (U.S.),
  QIAGEN (Netherlands), Roche (Switzerland),
  Bio-Rad Laboratories Inc. (U.S.), Trovagene Inc.
  (U.S.), Guardant Health, Inc. (U.S.), Janssen
  Diagnostics, LLC (U.S.), Fraunhofer-Gesellschaft
  (Germany), and MDxHealth SA (U.S.) are the major
  players in the liquid biopsy market.

http//www.marketsandmarkets.com/Market-Reports/li
quid-biopsy-market-13966350.html
10
Contact Us
Contact Mr. Rohan Markets and Markets UNIT no
802, Tower no. 7, SEZ Magarpatta city,
Hadapsar Pune, Maharashtra 411013,
India 1-888-600-6441 Email sales_at_marketsandmarket
s.com
http//www.linkedin.com/company/marketsandmarkets
http//www.marketsandmarkets.com/Market-Reports/li
quid-biopsy-market-13966350.html
11
About MarketsandMarkets
MarketsandMarkets is the global market research
and consulting company based in the U.S. We
publish strategically analyzed market research
reports and serve as a business intelligence
partner to Fortune 500 companies across the
world. MMs flagship competitive intelligence
and market research platform, "RT" connects over
200,000 markets and entire value chains for
deeper understanding of the unmet insights along
with market sizing and forecasts of niche
markets. The new included chapters on Methodology
and Benchmarking presented with high quality
analytical infographics in our reports gives
complete visibility of how the numbers have been
arrived and defend the accuracy of the
numbers. We at MarketsandMarkets are inspired
to help our clients grow by providing apt
business insight with our huge market
intelligence repository.
http//www.marketsandmarkets.com/Market-Reports/li
quid-biopsy-market-13966350.html